TissGeneSummary for TMEM225 |
Gene summary |
Basic gene information | Gene symbol | TMEM225 |
Gene name | transmembrane protein 225 | |
Synonyms | PMP22CD|PPP1R154 | |
Cytomap | UCSC genome browser: 11q24.1 | |
Type of gene | protein-coding | |
RefGenes | NM_001013743.2, | |
Description | PMP22 claudin domain-containing proteinprotein phosphatase 1, regulatory subunit 154 | |
Modification date | 20141207 | |
dbXrefs | HGNC : HGNC | |
Ensembl : ENSG00000204300 | ||
HPRD : 18492 | ||
Vega : OTTHUMG00000165959 | ||
Protein | UniProt: go to UniProt's Cross Reference DB Table | |
Expression | CleanEX: HS_TMEM225 | |
BioGPS: 338661 | ||
Pathway | NCI Pathway Interaction Database: TMEM225 | |
KEGG: TMEM225 | ||
REACTOME: TMEM225 | ||
Pathway Commons: TMEM225 | ||
Context | iHOP: TMEM225 | |
ligand binding site mutation search in PubMed: TMEM225 | ||
UCL Cancer Institute: TMEM225 | ||
Assigned class in TissGDB* | C | |
Included tissue-specific gene expression resources | HPA,GTEx | |
Specific-tissues in normal samples (assigned by TissGDB using HPA, TiGER, and GTEx) | Testis | |
Cancer types related to the specific-tissues in cancer samples (assigned by TissGDB using TCGA) | TGCT | |
Reference showing the relevant tissue of TMEM225 | ||
Description by TissGene annotations |
* Class A consists of genes with literature evidence and is part of the cTissGenes. Class B consists of only cTissGenes without additional evidence. The remaining genes belong to Class C. |
Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
GO ID | GO term | PubMed ID | GO:0010923 | negative regulation of phosphatase activity | 19389623 | GO:0010923 | negative regulation of phosphatase activity | 19389623 |
Top |
TissGeneExp for TMEM225 |
Gene expressions across 28 cancer types (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) |
Gene isoform expressions across 28 cancer types (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA pan-cancer tcga_rsem_isoform_tpm, version 2016-09-01) |
Gene expressions across normal tissues of GTEx data (GTEx GTEx_Analysis_v6_RNA-seq_RNA-SeQCv1.1.8_gene_rpkm.gct) - Here, we shows the matched tissue types only among our 28 cancer types. |
Different expressions across 14 cancer types with more than 10 samples between matched tumors and normals (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) |
- Significantly differentially expressed cancer types and information. (|Fold change|>1 and FDR<0.05) |
Cancer type | Mean(exp) in tumor | Mean(exp) in matched normal | Log2FC | P-val. | FDR |
Top |
TissGene-miRNA for TMEM225 |
Significantly anti-correlated miRNAs of TissGene across 28 cancer types (Gene-miRNA relations from TargetScanHuman Relsease 7.1, Conserved_Site_Context_Scores.txt.zip, 06.01.2016) (TCGA IlluminaHiSeq_miRNASeq, log2(RPM+1) data, version 2016-11-21) (TCGA IlluminaHiSeq_RNASeqV2, log2(normalized_count+1) data, version 2016-08-16) (Spearman’s Rank Correlation (p-value<0.05 and coefficient<-0.25)) |
Cancer type | miRNA id | miRNA accession | P-val. | Coeff. | # samples |
Top |
TissGeneMut for TMEM225 |
TissGeneSNV for TMEM225 |
nsSNV counts per each loci. Different colors of circles represent different cancer types. Circle size denotes number of samples. (TCGA somatic mutation (SNPs and small INDELs) data, version 2016-04-25) * Click on the image to enlarge it in a new window. |
Somatic nucleotide variants of TissGene across 28 cancer types (X-axis: cancer type and Y-axis: % of mutated samples) The numbers in parentheses are numbers of samples with mutation (nsSNVs). (TCGA somatic mutation (SNPs and small INDELs) data, version 2016-04-25) |
- nsSNVs sorted by frequency. |
AAchange | Cancer type | # samples |
p.E180K | SKCM | 3 |
p.R219H | LGG | 2 |
p.E183K | SKCM | 2 |
p.R219C | UCEC | 1 |
p.W223X | SKCM | 1 |
p.W19R | STAD | 1 |
p.E35V | LUAD | 1 |
p.Q126H | PAAD | 1 |
p.N13K | ESCA | 1 |
p.A206V | KIRC | 1 |
p.T71M | UCEC | 1 |
p.F132L | UCEC | 1 |
p.G27R | LUSC | 1 |
p.K176T | SKCM | 1 |
p.R201H | HNSC | 1 |
p.S17F | LGG | 1 |
p.E180K | PRAD | 1 |
p.D61G | STAD | 1 |
p.Y135C | HNSC | 1 |
p.Q94K | ESCA | 1 |
p.S187F | PAAD | 1 |
p.L212V | BLCA | 1 |
p.F107L | UCEC | 1 |
p.S152Y | UCEC | 1 |
p.V25M | BLCA | 1 |
p.S38L | SKCM | 1 |
p.S72L | THYM | 1 |
p.S17F | CESC | 1 |
p.M86I | SKCM | 1 |
p.L57R | STAD | 1 |
p.Y145* | LGG | 1 |
p.S211Y | UCEC | 1 |
p.D62N | SKCM | 1 |
p.D178Y | UCEC | 1 |
p.C162* | LUAD | 1 |
p.M51I | SKCM | 1 |
p.M130I | THYM | 1 |
p.S8G | LUAD | 1 |
p.P49T | HNSC | 1 |
p.S18F | SKCM | 1 |
p.C154Y | THYM | 1 |
p.R201H | LUAD | 1 |
p.R205C | COAD | 1 |
p.E180K | READ | 1 |
p.M141I | LUSC | 1 |
p.Q128R | STAD | 1 |
p.R219H | OV | 1 |
p.W58X | ESCA | 1 |
p.M26I | LUSC | 1 |
p.W58* | UCEC | 1 |
p.C181R | STAD | 1 |
p.E185D | UCEC | 1 |
p.V221I | THCA | 1 |
p.A43T | LUAD | 1 |
p.L74F | UCEC | 1 |
p.L172P | ACC | 1 |
p.W223* | SKCM | 1 |
p.K87T | READ | 1 |
p.Q94E | LUSC | 1 |
p.S72L | SKCM | 1 |
p.T143P | PAAD | 1 |
Top |
TissGeneCNV for TMEM225 |
Copy number variations of TissGene across 28 cancer types (X-axis: cancer type and Y-axis: % of CNV samples) (TCGA Gistic2_CopyNumber_Gistic2_all_data_by_genes, Gistic2 copy number data, version 2016-08-16) |
Top |
TissGeneFusions for TMEM225 |
Fusion genes including TissGene (ChimerDB 3.0, 2016-12-01 and TCGA fusion Portal 2015-12-01) |
Database | Src | Cancer type | Sample | Fusion gene | ORF | 5'-gene BP | 3'-gene BP |
Top |
TissGeneNet for TMEM225 |
Co-expressed gene networks based on protein-protein interaction data (CePIN) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (PINA2 ppi data) |
Top |
TissGeneProg for TMEM225 |
Kaplan-Meier plots with logrank tests of overall survival (OS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image to enlarge it in a new window. |
Kaplan-Meier plots with logrank test of relapse free survival (RFS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
Forest plot of Cox proportional hazard ratio (HR) and 95% CI of overall survival (OS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
Forest plot of Cox proportional hazard ratio (HR) and 95% CI of relapse free survival (RFS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
Top |
TissGeneClin for TMEM225 |
TissGeneDrug for TMEM225 |
Drug information targeting TissGene (DrugBank Version 5.0.6, 2017-04-01) |
DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
Top |
TissGeneDisease for TMEM225 |
Disease information associated with TissGene (DisGeNet, 2016-06-01) |
Disease ID | Disease name | # pubmeds | Source |